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The intact plasma proteome is of great interest in biomarker studies because intact proteins reﬂect posttranslational protein
processing such as phosphorylation that may correspond to disease status. We examined the utility of a solid-phase hexapeptide
ligand library in combination with conventional plasma proteomics modalities for comprehensive proﬁling of intact plasma
proteins.Plasmaproteinsweresequentiallyfractionatedusingdepletioncolumnsforalbuminandimmunoglobulin,andseparated
using an anion-exchange column. Proteins in each fraction were treated with a solid-phase hexapeptide ligand library and
compared to those without treatment. Two-dimensional diﬀerence gel electrophoresis demonstrated an increased number of
protein spots in the treated samples. Mass spectrometric studies of these protein spots with unique intensity in the treated samples
resulted in the identiﬁcation of high- and medium-abundance proteins. Our results demonstrated the possible utility of a solid-
phase hexapeptide ligand library to reveal greater number of intact plasma proteins. The characteristics of proteins with unique
aﬃnity to the library remain to be clariﬁed by more extensive mass spectrometric protein identiﬁcation, and optimized protocols
should be established for large-scale plasma biomarker studies.
1.Introduction
The plasma proteome has been extensively investigated with
the aim of biomarker development [1, 2]. Plasma is the most
accessible clinical material, and plasma biomarkers for early
diagnosis and monitoring the response to therapy and dis-
ease recurrence would be beneﬁcial for patients with cancer.
Because proteins released by tumors, particularly early-stage
tumors, are expected to exist in very low concentrations and
plasma contains various proteins with considerable hetero-
geneity between and within patients, the identiﬁcation of
novel plasma biomarkers represents a substantial challenge.
Global expression studies on intact plasma proteins are
of special interest in biomarker studies as the intact proteins
reﬂect the functional features of protein structure. Those
includeposttranslationalprocessingsuchasphosphorylation
and glycosylation. Peptide subsets from complex digests have
been analyzed for plasma proteomics, resulting in the iden-
tiﬁcation of low-abundance proteins such as tissue leakage
proteins[3]andbiomarkercandidates[4].However,analysis
of peptide digests may not be sensitive to posttranslational
protein processing, and may therefore not reveal many
relevant protein isoforms associated with disease status. To
date, much eﬀort has been devoted to detect trace intact
proteins in complex plasma samples.
The utility of a combinatorial hexapeptide ligand
library immobilized on a solid-phase matrix has been
reported, introduced to intact plasma proteomics [5–9], and2 International Journal of Proteomics
commercialized as ProteoMiner (Bio-Rad Laboratories, Her-
cules,CA,USA).ProteoMinercontainsmillionsofrandomly
synthesized hexapeptide ligands that are equally represented
w i t has e l e c t e dn u m b e ro ft a r g e t s .W h e nac o m p l e xp l a s m a
protein extract is exposed, the hexapeptide ligands for high-
abundance proteins are saturated, but the majority remains
unbound. In contrast, the proteins which do not saturate the
corresponding hexapeptide ligands and usually not observed
by the conventional methods will appear in the proteome
data. The approach of using a combinatorial hexapeptide
ligand library is diﬀerent from that of using depletion and
separation; thus, it reveals a novel aspect of the plasma
proteome. A recent report demonstrated that prefraction-
ation using a hexapeptide ligand library for shotgun mass
spectrometrystudiesidentiﬁedplasmaproteinsnotrecorded
in the Human Plasma Proteome Project [10]. The combined
use of a hexapeptide ligand library with depletion and
separation methods has also been a challenge in deeper
plasma proteomics [11], and the resulting protein contents
are examined by gel electrophoresis and mass spectrometry
[12, 13]. ProteoMiner has been used for disease biomarker
studiesinlungcancer[14]andli v ercanc er[15].Considering
that it will potentially visualize the unique plasma proteome
aspects, the application and optimization of a solid-phase
hexapeptide ligand library for disease biomarker studies
should be further investigated.
In this study, we examined the utility of a solid-phase
hexapeptide ligand library in combination with a depletion
column, an anion-exchange column, and 2D-DIGE that
allows an instant visual comparison of the protein patterns.
Proteinspots exhibiting prominent diﬀerencesbetween sam-
ples treated with and without the library were subjected to
mass spectrometry. Our study clearly demonstrated that the
combined use of the ProteoMiner and the other proteomics
modalities can visualize unique plasma proteome.
2.MaterialsandMethods
2.1. Sample Preparation. Frozen human plasma was pur-
chasedfromCosmobioKOJ(Tokyo, Japan).Aftertheplasma
was placed on ice, 40mL plasma was centrifuged and 30mL
supernatant was recovered for the following experiments.
2.2. Albumin Depletion. Albumin and other proteins were
separated using a HiTrap Blue HP column (5mL resin,
GE, Uppsala, Sweden) with the AKTA Explorer system
(GE) at a ﬂow rate of 1.0mL/min. The separation was
initiated by washing the column with rinse buﬀer (50mM
KH2PO4/Na2HPO4, pH 7.0) for 5min. Plasma (30mL)
was diluted with 60mL 50mM KH2PO4/Na2HPO4 (pH
7.0), and 9mL of the diluted plasma was injected. The
column was then washed with binding buﬀer (50mM
KH2PO4/Na2HPO4, pH 7.0) for 35min, and the ﬂow-
through fraction was collected. Bound proteins were eluted
from the column with elution buﬀer (50mM KHPO4,1 . 5M
KCl, pH 7.0) for 45min, and the bound fraction was
collected. The column was neutralized with rinse buﬀer for
20min. This process was repeated 10 times for a total of
90mL of diluted plasma.
One-third of the ﬂow-through and bound fractions,
approximately 150mL of each, was concentrated to 1.2mL
using a VIVA Spin 20 column (10K MWCO, 20mL capacity,
Sartorius, Gotteingen, Germany). Then, 1.0mL and 0.20mL
of the concentrated samples were subjected to treatment
with the solid-phase hexapeptide ligand library and 2D-
DIGE, respectively. Two-thirds of the ﬂow-through fraction,
approximately 300mL, was subjected to an immunodeple-
tion column.
2.3.ImmunoglobulinDepletion. Immunoglobulinwasdeple-
ted using the HiTrap Protein G HP column (1mL resin,
GE) with the AKTA Explorer system (GE) at a ﬂow rate
of 1.0mL/min. The depletion was initiated by washing the
column with rinse buﬀer (50mM KH2PO4/Na2HPO4,p H
7.0)for4min.After15mLoftheﬂow-throughfractionfrom
the HiTrap Blue HP column was injected, the column was
washed with binding buﬀer (50mM KH2PO4/Na2HPO4,p H
7.0) for 5min, and the ﬂow-through fraction was collected.
Bound proteins were eluted from the column with elution
buﬀer (0.1M glycine-HCl, pH 2.2) for 8min and collected
as the bound fraction. The collected bound fraction was
immediatelyneutralizedwithneutralizingbuﬀer(1.0MTris-
HCl, pH 9.0). The column was equilibrated with rinse buﬀer
for 5min for reuse. This process was repeated 20 times for
a total of two-thirds of the ﬂow-through fraction from the
HiTrap Blue HP column (approximately 300mL).
Half of the ﬂow-through and bound fractions (approx-
imately 200mL and 80mL, resp.) were concentrated to
1.2mL and 0.25mL, respectively, using VIVA Spin 20
columns (Sartorius). Then, 1.0mL of the concentrated ﬂow-
through fraction and 0.20mL of the concentrated bound
fraction were subjected to treatment with the solid-phase
ligand library, and the remaining samples were subjected
to 2D-DIGE. Another half of the ﬂow-through fraction
(approximately 200mL) was concentrated to 2.0mL using
the VIVA Spin 20 column (Sartorius). After diluting with
38mLof25mMTris-HCl(pH9.0),thesamplewassubjected
to separation on an anion-exchange column.
2.4. Anion Exchange. The ﬂow-through fraction from the
HiTrap Protein G HP column was separated using the
Resource Q column (1mL resin, 6.4mm id × 30mm, GE)
with the AKTA Explorer system (GE) at a ﬂow rate of
3.0mL/min. The separation was initiated by washing the
column with rinse buﬀer (25mM Tris-HCl, pH 9.0) for
4min, and 5mL of the ﬂow-through fraction from the
HiTrap Protein G HP column was injected. The separations
were performed using a stepwise NaCl gradient as follows:
0, 100, 150, 200, 250, and 1000mM for 5min each. All
samples contained 25mM Tris-HCl, pH 9.0. The column
was washed with rinse buﬀer (25mM Tris-HCl, pH 9.0) for
5min. This process was repeated 8 times for a total of 40mL
of the diluted ﬂow-through fraction from the HiTrap Protein
GH Pc o l u m n .
The collected samples were concentrated to 0.25mL, and
the buﬀer was exchanged gradually with 25mM Tris-HCl
(pH 9.0) using the VIVA Spin 20 column (Sartorius). Then,International Journal of Proteomics 3
0.2mL and 0.05mL were subjected to treatment with the
solid-phase ligand library and 2D-DIGE, respectively.
2.5. Treatment with the Solid-Phase Ligand Library. A solid-
phase combinatorial library of hexapeptides was purchased
from Bio-Rad Laboratories (ProteoMiner kit). Unprocessed
plasma (1mL) and the ﬂow-through fractions from the
HiTrap Blue HP and HiTrap Protein G HP columns were
treated using the ProteoMiner large-capacity kit, and 0.2mL
of the bound fraction from the HiTrap Protein G HP
column, and all fractions from the Resource Q column were
treated using the ProteoMiner small-capacity kit. After 2h
of incubation at room temperature, the unbound fraction
was washed out by centrifugation. After rinsing, the bound
sample was eluted with an elution reagent containing 8M
urea, 2% CHAPS, and 5% acetic acid, according to the
manufacturer’s instructions.
2.6. Measurement of Protein Concentration. Protein concen-
tration was measured using a protein assay kit (Bio-Rad),
according to the manufacturer’s instructions (Table 1).
2.7. SDS-PAGE. Protein samples (1μg) were examined by
electrophoresis using 18-well precast 12.5% polyacrylamide
gel plates (e-PAGEL, ATTO, Tokyo, Japan). Electrophoresis
was performed at a constant current of 40mA for 80min
and using the page Run AE6531 system [16]. Silver staining
was performed using the Silver Stain KANTO III kit (Kanto
Chemical, Tokyo, Japan), according to the manufacturer’s
instructions.
2.8. 2D-DIGE. 2D-DIGE was performed as described pre-
viously [17]. Brieﬂy, protein samples (20μg) were labeled
with the Cy3 or Cy5 ﬂuorescent dye (CyDye DIGE Fluor
saturation dye, GE), and diﬀerentially labeled protein sam-
ples were mixed. After dividing into 3, the labeled protein
samples were separated by 2D-PAGE. The ﬁrst-dimension
separation was performed using a 24cm length immobiline
gel (IPG, pI 4–7, GE) and Multiphor II (GE) whereas the
second-dimension separation was performed using gradient
gels prepared in house and EttanDalttwelve (GE). The gels
were scanned using a laser scanner (Typhoon Trio, GE) at
an appropriate wavelength for Cy3 or Cy5. The Cy3 and Cy5
intensities were compared in the same gel using the Proge-
nesis SameSpots software (version 4.0; Nonlinear Dynamics,
Newcastle, UK). ProteoMiner-treated and untreated samples
were labeled with Cy3 and Cy5, respectively, or with Cy5
and Cy3, respectively. Six gels were run for each sample. The
average value of the intensity ratio was calculated among the
triplicate gels for all protein spots and then averaged between
the 2 samples for further study. Spot intensity data were
exported from the Progenesis SameSpots software as Excel
ﬁles amenable to numerical data analysis.
2.9. Mass Spectrometric Protein Identiﬁcation. Proteins were
extracted from the protein spots by in-gel digestion, as
reported previously [17]. Brieﬂy, protein samples (100μg)
were labeled with Cy3 and separated by 2D-PAGE. The
Table 1: List of the identiﬁed proteins and their reported concen-
tration.
Protein name Normal concentration
μg/mL
Adiponectin 2–17
Albumin 35000–52000
Alpha-1-antitrypsin 900–2000
Alpha-1B-glycoprotein 150–300
Alpha-2-macroglobulin 1300–3000
Apolipoprotein A-I 1000–2000
Apolipoprotein A-II 190–300
Apolipoprotein A-IV 110–220
Apolipoprotein D 60–90
Apolipoprotein E 30–60
Carboxypeptidase N 30
Ceruloplasmin 190–370
Clusterin 250–420
Coagulation factor X 10
Complement C3 900–1800
Complement C4-A 25–90
Fibrinogen beta chain 520–1420
Fibrinogen gamma chain 490–1340
Ficolin-2 1–12
Ficolin-3 3–54
Haptoglobin 200–2000
Haptoglobin-related protein 32–41
Inter-alpha-trypsin inhibitor
(heavy chain H3) 100–200
Paraoxonase/arylesterase 1 58–61
Prothrombin 100
Serotransferrin 2000–3600
Transthyretin 200–400
Vitronectin 240–530
Zinc-alpha-2-glycoprotein 60–80
The table with the references for the protein concentration is shown in
Supplementary Table 7 in Supplemrntary material available online at doi:
10.1155/2011/39615.
protein spots were then recovered from the gel pieces using
an automated spot recovery machine. The recovered protein
spots were extensively washed with a solution containing
acetonitrile and ammonium bicarbonate minimum and
treated with trypsin (Promega, Madison, WI, USA) at 37◦C
overnight. The tryptic digests were recovered from the gel
pieces, concentrated by vacuum, and resolubilized with 0.1%
triﬂuoroacetic acid. The ﬁnal tryptic digests were subjected
to mass spectrometry, which was performed using the LXQ
linear ion trap mass spectrometer (Thermo Electron, San
Jose, CA, USA). The Mascot software (version 2.3.0; Matrix
Science, London, UK) was used to search for the mass of the
peptide ion peaks against the SWISS-PROT database (Homo
sapiens, 471472 sequences in Sprot 57.5 fasta ﬁle). The
search parameters were as follows: trypsin digestion allowing
up to 3 missed tryptic cleavages, ﬁxed modiﬁcations of4 International Journal of Proteomics
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Figure 1:Overviewofproteinfractionationbysequentialuseof3diﬀerentcolumnstoseparateplasmaproteins.Allfractionsweresubjected
to ProteoMiner and 2D-DIGE.
carbamidomethyl, variable modiﬁcations of oxidation, 1+,
2+,a n d3 + peptide charge, peptide mass tolerance of 2.0Da,
and use of MS/MS tolerance of 1.0Da for all tryptic-mass
searches.
3. Results andDiscussion
We previously reported the utility of combining multidi-
mensional chromatography and 2D-DIGE for intact plasma
proteomics. Extensive fractionation by the diﬀerent separa-
tion modes increased the number of protein spots on 2D-
DIGE and allowed a quantitative comparison between the
plasma samples fromhealthydonors and those frompatients
with lung adenocarcinoma [18] and pancreatic cancer [19].
However, mass spectrometric protein identiﬁcation revealed
that protein spots with a signiﬁcant diﬀerence between
the sample groups corresponded to high- and medium-
abundance proteins such as acute-phase proteins, but no
known plasma tumor markers were detected. Thus, we
concluded that further investigations are needed to reveal
low-abundance proteins for biomarker studies. In this study,
we examined whether a novel technology, a solid-phase
hexapeptide ligand library could improve the linkage of
multidimensional chromatography and 2D-DIGE.
3.1. Overall View of Protein Fractionation: Comparison and
Detection. The overall view of sequential protein separation
is shown in Figure 1. A sample equivalent to 10mL plasma
was separated using 3 diﬀerent columns and then treated
withthesolid-phasehexapeptideligandlibraryProteoMiner.
The ProteoMiner-treated and untreated samples were com-
pared using 2D-DIGE by labeling them with diﬀerent ﬂuo-
rescent dyes and separating the labeled proteins on an identi-
cal gel. The protein spots with signiﬁcantly diﬀerent intensi-
ties between the ProteoMiner-treated and untreated samples
were subjected to mass spectrometry to identify the proteins.
The number of observable low-abundance proteins was
aﬀected by the initial amount of plasma sample and the
sensitivity of the ﬁnal quantiﬁcation method. We used a
relatively large volume of plasma sample (10mL) as the
initial material. The immunodepletion columns allow the
use of only a small volume of plasma sample for separa-
tion. Furthermore, a signiﬁcantly larger number of plasma
samples should be examined to obtain conclusive results for
biomarker development. A larger volume of samples can be
manipulated by repeatedly using the same immunodepletion
column. Although it is quite feasible, special attention may
be required to maintain reproducibility during a long period
of use. In this study, we used Blue Sepharose and ProteinInternational Journal of Proteomics 5
G-Sepharose columns in a sequential manner to deplete
albumin and subsequently immunoglobulin and to min-
imize repeated use of the same column. Although these
columns may have less sensitivity than an immunodepletion
column and deplete nontargeted proteins that may bind to
albumin and immunoglobulin, a larger volume of plasma
sample can be treated in individual procedures. A previous
study indicated that Cibacron Blue beads remove a major
portion of the albumin but with concomitant loss of
potentially important peptides and proteins [20]. Thus,
we examined both the column-bound and ﬂow-through
fractions (Figure 1). Although the speciﬁcity of Cibacron
Blue beads was not validated in this study, as the purpose
of Cibacron Blue was to reduce the complexity of plasma
sample, it should not be problem.
To avoid possible redundant proteins in the neighboring
fractions as much as possible when utilizing the anion-
exchange column, we used stepwise elution and fractiona-
tion; once all proteins were eluted, the next elution buﬀer
was applied to the column (Figure 1). Considering the com-
plexity of the samples and resolution of an anion-exchange
column,extensivefractionationwithagradientbuﬀersystem
may result in redundant contents among the fractions.
We employed 6 stepwise fractionations by monitoring the
fraction contents using SDS-PAGE (data not shown).
3.2. High Reproducibility of Protein Fractionation by Chro-
matography. The ultraviolet detection (280nm) trace for
eachrun demonstratedconsistent separation of albuminand
immunoglobulin from the depletion and anion-exchange
columns. This high reproducibility may suggest the possible
utilities of this approach for biomarker studies (Supple-
mentary Figure 1). High quantitative and qualitative repro-
ducibility of the solid-phase hexapeptide ligand library Pro-
teoMiner has been conﬁrmed in previous reports [21, 22].
3.3.DemonstrationoftheEﬀectsofFractionationandDynamic
Range Reduction. We examined the eﬀects of sequential
plasma protein fractionation using 3 columns and the
reduction of dynamic range by ProteoMiner (Figure 2).
The contents of the fractionated samples were apparently
diﬀerentfromeachother.Notably,theproteinsamplebound
to the Blue Sepharose and Protein G-Sepharose columns
included many proteins that should be diﬀerent from the
targeted proteins, according to their molecular weights.
Treatment of the fractionated samples with ProteoMiner
enhanced the proteins that were not observed, except for
those bound to the Protein G-Sepharose column. Treatment
of the bound fraction from the Protein G-Sepharose column
with ProteoMiner did not result in a greater number of
observable proteins. This may have been due to the low
complexity and narrow dynamic range of proteins in the
boundfractionfromtheProteinG-Sepharosecolumn.There
was one order of magnitude in concentration diﬀerence
for the observed protein bands in the ProteoMiner-treated
sample. These observations may reﬂect that the aﬃnity of
proteins for the peptide may not be equal and even the
number of peptides bound on the beads is equal, the amount
of proteins bound to the ProteoMiner may be diﬀerent
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Figure 2: Overview of the protein contents fractionated by
liquid chromatography and ProteoMiner. The fractionated protein
sampleswereloadedontoSDS-PAGE,andtheproteincontentswere
visualized by silver staining.
depending on their aﬃnity. This fraction contained similar
amounts of only 4 major proteins, as revealed by SDS-PAGE
(Figure 2), and they may have been absorbed to ProteoMiner
in proportion to their original amount.
Theconcentrationandamountofproteinsamplesbefore
and after ProteoMiner treatment are summarized in Supple-
mentary Table 1. The recovery rate from ProteoMiner was
between0.54and6.33%,suggestingthatauniquepopulation
of protein species selectively bound to ProteoMiner. This
assumption was supported by the SDS-PAGE data, except
the bound fraction from the Protein G-Sepharose column
which included only 4 major proteins that were bound to
ProteoMiner (Figure 2).
3.4. Higher Separation of Fractionated Protein Samples and an
Evaluation of the Eﬀects of ProteoMiner Treatment. Although
SDS-PAGE separated individual proteins with higher6 International Journal of Proteomics
resolution than chromatography in this study, using it for a
quantitative comparison in a biomarker study may be trou-
blesome because many protein bands obviously overlapped
(Figure 2). Thus, we subjected the fractionated samples
to 2D-DIGE in order to separate the proteins with higher
resolution. Bandow compared ProteoMiner-treated and
untreated plasma samples using conventional 2D-PAGE and
demonstrated substantial diﬀerences between unprocessed
and immunodepleted plasma samples [11]. In 2D-DIGE, 2
protein samples were labeled with diﬀerent ﬂuorescent dyes,
mixed, and separated by 2D-PAGE. Because the 2 samples
wereseparatedonanidentical2D-PAGE, gel-to-gelvariation
was compensated. In addition, the wide dynamic range of
the ﬂuorescent dyes enabled a quantitative comparison.
2D-DIGE has been applied to compare the performance of
ProteoMiner with an immunodepletion column [12]. We
further extended the evaluation of the utility of ProteoMiner
by loading a high amount of protein and examining the
proteins separated by an anion-exchange column.
The ﬂuorescent 2D-PAGE images of the ProteoMiner-
treated and untreated samples were overlaid with diﬀerent
colors, so that the unique protein contents were visualized
(Figures 3 and 4). The results of experiments in which the
ﬂuorescent dyes were swapped are shown in Supplementary
Figure 2. Consistent with the SDS-PAGE results (Figure 2),
Figure 3 demonstrates that the approach involving depletion
of high-abundance proteins and multidimensional separa-
tion was an eﬀective prefractionation method to increase
the number of protein spots, and the use of ProteoMiner
treatment also contributed to reveal more plasma proteins.
Because these fractionation methods are based on diﬀerent
binding properties of proteins, their combined use revealed
additional plasma proteins.
The number of observed protein spots on 2D gel elec-
trophoresis is summarized in Supplementary Table2. Over-
all, the total number of protein spots increased by treating
the samples with ProteoMiner, except for the bound fraction
from the Protein G-Sepharose column. This observation
suggests that ProteoMiner may be a useful tool to observe a
greater number of protein spots in prefractionated samples.
We compared the protein spots of the samples with and
without ProteoMiner treatment (Supplementary Table3).
Dependingonthecriteria,diﬀerentnumbersofproteinspots
showed signiﬁcantly diﬀerent intensities. Although the total
number of protein spots increased by treating the samples
with ProteoMiner (Supplementary Table 2), many protein
spots revealed decreased intensity with treatment, suggesting
the selective enrichment by ProteoMiner.
3.5. Mass Spectrometric Identiﬁcation of Proteins with Dif-
ferent Aﬃnities to ProteoMiner. To reveal the characteristics
of proteins with a particularly high or low aﬃnity to
ProteoMiner, among the protein spots with greater than
5-fold diﬀerences (Supplementary Table 3), we selected
those with the top 10% diﬀerent intensities between the
ProteoMiner-treated and untreated samples in each fraction
and subjected them to mass spectrometric identiﬁcation.
A total of 200 protein spots were subjected to mass spec-
trometry, and a positive identiﬁcation was obtained for 128
(Supplementary Table 4). A list of the identiﬁed proteins
is provided in Supplementary Table 5, and data supporting
protein identiﬁcation are shown in Supplementary Table 6.
These 128 protein spots corresponded to 29 unique proteins.
Because the fold diﬀerence of the protein spots in the bound
fraction from the Protein G-Sepharose column was less
than 4, we did not examine them. Of the original plasma
samples, vitronectin and albumin were most aﬀected by
ProteoMiner treatment and disappeared after depletion and
fractionation using the anion-exchange column. The other
proteins were identiﬁed as enriched (or nonenriched) by
ProteoMinertreatment.ProteinsboundtoProteoMinerhave
been reported in previous studies in which the proteins
were globally identiﬁed by mass spectrometry. Dwivedi et
al. demonstrated that albumin, alpha 1-antitrypsin, alpha
2-macroglobulin, apolipoprotein A-I, apolipoprotein A-II,
haptoglobin-related protein, and serotransferrin have high
aﬃnity to ProteoMiner [21]. In addition, Beseme et al. iden-
tiﬁed apolipoprotein A-IV, apolipoprotein D, apolipopro-
tein E, ceruloplasmin, complement C3, ﬁbrinogen beta,
ﬁbrinogen gamma, ﬁcolin-2, ﬁcolin-3, paroxonase I, pro-
thrombin, transthyretin, and vitronectin [23]. The protein
concentrations identiﬁed in this study are summarized in
Supplementary Table6. According to the literatures, the
identiﬁed proteins were classiﬁed as high- and medium-
abundance proteins. Adiponectin and the carboxypeptidase
N catalytic chain are not reported in previous studies, in
which ProteoMiner-treated samples were examined by 2D-
PAGE and mass spectrometry.
Adiponectin is an adipocytokine [24–27] and plays a
protective role against obesity-related disorders such as
metabolic syndrome [28], type 2 diabetes [29], and cardio-
vascular disease [30]. Low levels of plasma adiponectin are
associated with obesity [31] and many types of malignancies
suchaslivercancer[32],breastcancer[33],pancreaticcancer
[34], and endometrial cancer [35]. An epidemiological study
suggested that adiponectin is involved in early colorectal
carcinogenesis [36], and that a low circulating adiponectin
level is correlated with a poor prognosis in patients with
colorectal cancer [37]. The molecular backgrounds of these
observations may be attributable to the antiproliferative
eﬀects of adiponectin on cancer cells [38].
Carboxypeptidase N (CPN), which is also known as kin-
inase I, arginine carboxypeptidase, and anaphylatoxin inac-
tivator, is a zinc ﬁnger metalloprotease. It cleaves basic lysine
and arginine residues from the carboxy terminal of proteins
[39]. CPN is produced in the liver and secreted into the
plasma.Itmodulatestheactivityofcytokinessuchasstromal
cell-derived factor-1 alpha [40]. The association of CPN1
with malignancy and other diseases has not been reported,
and the clinical utility of CPN1 has not been suggested.
The working hypothesis of this study was that the com-
bined use of diﬀerent separation methods, including a solid-
phase hexapeptide ligand library, would increase the number
of observable proteins, and ﬁnally visualize the proteome
that may not be observed otherwise. By loading a high
amountofproteinandusingextensiveprefractionationtech-
niques prior to using ProteoMiner, trace proteins became
visible in SDS-PAGE, and the number of protein spots onInternational Journal of Proteomics 7
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Figure 3: Eﬀects of ProteoMiner treatment were examined by 2D-DIGE. The ProteoMiner-treated and untreated samples were labeled with
Cy3 and Cy5, respectively, mixed, and separated by 2D gel electrophoresis. Note that a signiﬁcant number of protein spots showed diﬀerent
intensities between the 2 samples. The dye-swapped images are shown in Supplementary Figure2. (a) Original plasma; (b) ﬂow-through
fraction of HiTrap Blue HP column; (c) binding fraction of HiTrap Blue HP column. (d) Flow-through fraction of HiTrap Protein G HP
column. (e) Binding fraction of HiTrap Protein G HP column; 0mM fraction. (f) 100mM fraction. (g) 150mM. (h) 200mM. (i) 250mM.
(j) 1M fraction. (k) Resource Q column.8 International Journal of Proteomics
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Figure 4: Localization of protein spots showing diﬀerent intensities between the ProteoMinor-treated and untreated samples. Panels (a–k)
correspond to those in Figure 3. The protein spot numbers corresponds to those in Supplementary Tables 5 and 6. −/−: number of protein
spots without ProteoMiner treatment/those with ProteoMiner treatment.
2D-DIGE increased signiﬁcantly. This approach may pave
a way to a novel strategy for intact plasma proteomics. In
contrast, the present results of mass spectrometric protein
identiﬁcation did not support the use of a solid-phase
hexapeptide ligand library to enrich low-abundance pro-
teins. It may be because our present approach had 3 limita-
tions. First, mass spectrometric identiﬁcation wasperformed
for proteins with a greater prominent diﬀerence between
the samples with or without ProteoMiner treatment, and
only 128 of 200 proteins were successfully identiﬁed (Sup-
plementary Table 4), probably because of the low protein
amount. Proteins with a smaller diﬀerence or amount may
include trace proteins. Although we optimized the protocols
for mass spectrometric protein identiﬁcation because the
sensitivity of the ﬂuorescent dye in the 2D-DIGE was very
high, not all protein spots on 2D-DIGE could be identiﬁed
by mass spectrometry. To evaluate enriched proteins, the
complementary use of an LC-MS/MS shotgun approach may
be worth considering. Second, proteins from ProteoMiner
were recovered by a single-step elution with 8M urea, 2%
CHAPS, and 5% acetic acid, according to the manufacturer’s
instructions (Bio-Rad). However, because proteins may have
interacted with hexapeptide ligand libraries in all possible
modes, the absolute elution process may require sequential
s t e p so rm o r es t r i n g e n tb u ﬀer conditions such as boiling
10% SDS with 3% DTE [41]. Furthermore, various binding
conditions may also be worth considering to capture whole
binding proteins [9]. Third, considering the practical use of
trace proteins in a biomarker study, we used as much sample
as possible for identifying them and examined 10mL plasma
samples as an initial source. However, a larger volume of
plasma sample, such as 100mL, might be needed to collect
rare proteins. In practice, such a high volume of plasma is
rarely obtained for many cases in biomarker studies, and
we may need to optimize the protocols for use of 10mL
plasma. For instance, we identify the biomarker candidates
using 100mL plasma, and using speciﬁc antibody against the
identiﬁedcandidate,wewillbeabletoscreenarelativelylarge
number of samples with 10mL volume or less.
The combined use of the ProteoMiner and the proteomic
modalities in this study may enable the quantitative compar-
ison for biomarker studies. We demonstrated that the liquid
chromatography was quantitatively reproducible (Supple-
mentary Figure 1), and the quantitative reproducibility of
the ProteoMiner and 2D-DIGE was previously reported [10,
17]. We may further need to examine how the combined10 International Journal of Proteomics
use of such reproducible methods generate the results in a
reproducible way, considering the degree of diﬀerences that
we expect between the samples to be compared.
4. Conclusions
The use of ProteoMiner in combination with conventional
proteomic modalities such as depletion and anion-exchange
columns signiﬁcantly enhanced trace proteins on SDS-PAGE
and increased the number of protein spots on 2D-DIGE,
suggesting that the use of a solid-phase hexapeptide ligand
libraryhasgreatpotentialforintactplasmaproteomics.Mass
spectrometric protein identiﬁcation revealed that high- and
middle-abundance proteins were enriched by ProteoMiner,
and the characteristics of proteins with unique aﬃnity to a
solid-phase hexapeptide ligand library remain to be clariﬁed
by more extensive mass spectrometric protein identiﬁcation.
Although use of ProteoMiner for biomarker studies is quite
feasible and attractive, more extensive characterization of
binding proteins and optimized protocols are required for
large-scale biomarker studies.
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